Cargando…

Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models

SIMPLE SUMMARY: The tyrosine kinase inhibitor (TKI) imatinib was the first targeted therapy to show clinical efficacy against chronic myeloid leukemia (CML) through inhibition of the breakpoint cluster region–Abelson murine leukemia viral oncogene homolog (BCR-ABL), which is responsible for the dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muselli, Fabien, Mourgues, Lucas, Morcos, Rita, Rochet, Nathalie, Nebout, Marielle, Guerci-Bresler, Agnès, Faller, Douglas V, William, Robert M, Mhaidly, Rana, Verhoeyen, Els, Legros, Laurence, Peyron, Jean-François, Mary, Didier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038300/ https://www.ncbi.nlm.nih.gov/pubmed/33918475 http://dx.doi.org/10.3390/cancers13071693

Ejemplares similares

Repurposing the Bis-Biguanide Alexidine in Combination with Tyrosine Kinase Inhibitors to Eliminate Leukemic Stem/Progenitor Cells in Chronic Myeloid Leukemia
por: Muselli, Fabien, et al.
Publicado: (2023)

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
por: Mhaidly, Rana, et al.
Publicado: (2020)

Growth effect of tki treatment in childhood CML
por: Jeon, Yeon Jin, et al.
Publicado: (2015)

Is There a Role for Dose Modification of TKI Therapy in CML?
por: Copland, M.
Publicado: (2019)

Drug Therapy in the Progressed CML Patient with multi-TKI Failure
por: Haznedaroglu, Ibrahim C.
Publicado: (2015)

New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP
por: Mhaidly, Rana, et al.
Publicado: (2020)

Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma
por: Ramdial, Jeremy L., et al.
Publicado: (2019)

PKCα and PKCδ: Friends and Rivals
por: Black, Jennifer D., et al.
Publicado: (2022)

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
por: Masiello, David, et al.
Publicado: (2009)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

Monitoring of immunity against leukemia stem cell in CML patients after cessation of TKI
por: Matsushita, Maiko, et al.
Publicado: (2015)

Variable Behavior of iPSCs Derived from CML Patients for Response to TKI and Hematopoietic Differentiation
por: Bedel, Aurélie, et al.
Publicado: (2013)

Delayed Diagnosis and Multi-TKI Intolerance: A Case Report of CML Concurrent With COVID-19
por: Luan, Chengxin, et al.
Publicado: (2022)

Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia
por: Muselli, Fabien, et al.
Publicado: (2019)

Differential Roles of the PKC Novel Isoforms, PKCδ and PKCε, in Mouse and Human Platelets
por: Pears, Catherine J., et al.
Publicado: (2008)

PKCδ Blues for the β-Cell
por: Schmitz-Peiffer, Carsten, et al.
Publicado: (2010)

Re-balance of memory T cell subsets in peripheral blood from patients with CML after TKI treatment
por: Yao, Danlin, et al.
Publicado: (2017)

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients
por: Tiribelli, Mario, et al.
Publicado: (2018)

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

Evaluation of CML TKI Induced Cardiovascular Toxicity and Development of Potential Rescue Strategies in a Zebrafish Model
por: Cheng, Shan, et al.
Publicado: (2021)

Overexpressed PKCδ Downregulates the Expression of PKCα in B16F10 Melanoma: Induction of Apoptosis by PKCδ via Ceramide Generation
por: Halder, Kuntal, et al.
Publicado: (2014)

Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance
por: Herrmann, Andreas B., et al.
Publicado: (2020)

P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE
por: Semerad, Lukas, et al.
Publicado: (2023)

Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells
por: Lin, Hanyang, et al.
Publicado: (2014)

Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
por: Glauche, Ingmar, et al.
Publicado: (2018)

Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients
por: Lavrov, Alexander V., et al.
Publicado: (2019)

PVR and ICAM-1 on Blast Crisis CML Stem and Progenitor Cells with TKI Resistance Confer Susceptibility to NK Cells
por: Kim, Nayoung, et al.
Publicado: (2020)

Blast Crisis of CML After TKI Discontinuation in a Patient With Previous Stable Deep Molecular Response: Is It Safe to Stop?
por: Papalexandri, Apostolia, et al.
Publicado: (2018)

Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: Results from real-world practice
por: Chen, Yilin, et al.
Publicado: (2023)

B7-H4 expression is upregulated by PKCδ activation and contributes to PKCδ-induced cell motility in colorectal cancer
por: Zhou, Bin, et al.
Publicado: (2022)

New Drug Repositioning Candidates for T-ALL Identified Via Human/Murine Gene Signature Comparison
por: Bonnet, Raphaël, et al.
Publicado: (2020)

PKCδ regulates the vascular biology in diabetic atherosclerosis
por: Qin, Peiliang, et al.
Publicado: (2023)

PKCδ deficiency inhibits fetal development and is associated with heart elastic fiber hyperplasia and lung inflammation in adult PKCδ knockout mice
por: Niino, Yuko S., et al.
Publicado: (2021)

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)
por: Fujisawa, Shin, et al.
Publicado: (2018)

Acadesine Kills Chronic Myelogenous Leukemia (CML) Cells through PKC-Dependent Induction of Autophagic Cell Death
por: Robert, Guillaume, et al.
Publicado: (2009)

Role of PKCδ in Insulin Sensitivity and Skeletal Muscle Metabolism
por: Li, Mengyao, et al.
Publicado: (2015)

Control of nuclear-cytoplasmic shuttling of Ankrd54 by PKCδ
por: Samuels, Amy L, et al.
Publicado: (2017)

Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients
por: Cutica, Ilaria, et al.
Publicado: (2022)

Role of FGFR2b expression and signaling in keratinocyte differentiation: sequential involvement of PKCδ and PKCα
por: Rosato, Benedetta, et al.
Publicado: (2018)

IRE1α overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response
por: Martinez-Turtos, Adriana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_inauq0agunjaaravcmqebhjvb2